Duncan Jason has filed 9 insider transactions across 1 company since December 2023.
Most recent transaction: a grant/award of 750000 shares of Neumora Therapeutics, Inc. ($NMRA) on January 08, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 8, 2026 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | A | Stock Option (Right to Buy) | 750000 | $0.00 | 750,000.0000 | 167,089,114 | 9999.99% | 0.45% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | D | Stock Option (Right to Buy) | 500000 | $0.00 | 0.0000 | 161,978,923 | 100.00% | 0.31% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 161,978,923 | 9999.99% | 0.25% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 161,978,923 | 9999.99% | 0.31% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | D | Stock Option (Right to Buy) | 400000 | $0.00 | 0.0000 | 161,978,923 | 100.00% | 0.25% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | D | Stock Option (Right to Buy) | 400000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | See Remarks | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 11, 2023 | Neumora Therapeutics, Inc. | $NMRA | Duncan Jason | Chief Legal Officer | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |